C WorldWide Group Holding A S Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

C WorldWide Group Holding A S cut its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 23.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,557 shares of the pharmaceutical company's stock after selling 22,000 shares during the quarter. Vertex Pharmaceuticals accounts for about 0.4% of C WorldWide Group Holding A S's investment portfolio, making the stock its 27th largest holding. C WorldWide Group Holding A S's holdings in Vertex Pharmaceuticals were worth $29,116,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Headlands Technologies LLC grew its stake in shares of Vertex Pharmaceuticals by 17.0% in the fourth quarter. Headlands Technologies LLC now owns 4,709 shares of the pharmaceutical company's stock worth $1,916,000 after acquiring an additional 685 shares during the period. Kovack Advisors Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 3.9% in the fourth quarter. Kovack Advisors Inc. now owns 1,080 shares of the pharmaceutical company's stock worth $439,000 after buying an additional 41 shares during the last quarter. Callan Capital LLC boosted its holdings in shares of Vertex Pharmaceuticals by 281.0% in the fourth quarter. Callan Capital LLC now owns 4,191 shares of the pharmaceutical company's stock worth $1,705,000 after buying an additional 3,091 shares during the last quarter. Motley Fool Asset Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 5.0% in the fourth quarter. Motley Fool Asset Management LLC now owns 7,593 shares of the pharmaceutical company's stock worth $3,090,000 after buying an additional 361 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Vertex Pharmaceuticals by 9.7% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 203,632 shares of the pharmaceutical company's stock worth $82,856,000 after buying an additional 18,002 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CAO Kristen Ambrose sold 1,374 shares of the company's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $577,409.76. Following the transaction, the chief accounting officer now directly owns 9,676 shares in the company, valued at $4,066,242.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the company's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. Insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of research reports. Barclays raised their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an "overweight" rating in a report on Tuesday, February 6th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 20th. Sanford C. Bernstein downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Friday, February 2nd. Truist Financial lifted their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a "buy" rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group reaffirmed a "sell" rating and set a $371.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $429.45.

Vertex Pharmaceuticals Price Performance

VRTX traded down $0.22 during trading hours on Friday, hitting $397.48. The company's stock had a trading volume of 682,467 shares, compared to its average volume of 909,553. The business's 50-day moving average price is $411.60 and its 200-day moving average price is $398.93. Vertex Pharmaceuticals Incorporated has a 12 month low of $320.01 and a 12 month high of $448.40. The stock has a market cap of $102.73 billion, a price-to-earnings ratio of 28.62, a P/E/G ratio of 1.87 and a beta of 0.35. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion for the quarter, compared to analysts' expectations of $2.50 billion. During the same quarter in the previous year, the business posted $3.33 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.